
TWST — Twist Bioscience Corp
NASDAQ · Healthcare · Diagnostics & Research
$135.13
+$3.07 (+2.32%)
Twist Bioscience Corp (TWST) is a diagnostics & research company listed on NASDAQ. It is led by Emily Marine Leproust Ph.D., based in 681 Gateway Boulevard, South San Francisco, CA, United States, 94080, with about 979 employees. Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Net income was -$77.7M. TWST currently screens at market cap $5.16B.
Use this TWST page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the TWST quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the TWST SEC filings page. Lician reads the product cache first so this HTML stays unique to Twist Bioscience Corp even when a live quote feed is slow.
About Twist Bioscience Corp
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
TWST Key Statistics
Market Cap
$5.16B
Volume
864,945
Previous Close
$140.80
Day Range
$141.41 – $154.47
P/B Ratio
11.35
EPS
-$1.30
Revenue
$0.00
Net Income
-$77.67M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
979
TWST Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$77.67M | -$208.73M | -$204.62M | -$217.86M |
| EPS (Diluted) | -$1.30 | -$3.60 | -$3.60 | -$4.04 |
Total Assets
$641.86M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$183.05M
Operating Cash Flow
-$47.63M
Free Cash Flow
$0.00
Twist Bioscience Corp Company Information
- Co-Founder, Board Chair & CEO
- Emily Marine Leproust Ph.D.
- Headquarters
- 681 Gateway Boulevard, South San Francisco, CA, United States, 94080
- Website
- www.twistbioscience.com
- Phone
- 800 719 0671
- IPO / Founded
- 2018-10-31
- Sector
- Healthcare
- Industry
- Diagnostics & Research